Compare Super Group (SGHC) Limited Ordinary Shares (SGHC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Super Group (SGHC) Limited Ordinary Shares vs Tango Therapeutics Inc. — how do they compare? Super Group (SGHC) Limited Ordinary Shares trades at $11.1 (market cap $5.65B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Super Group (SGHC) Limited Ordinary Shares is the larger of the two by market cap, and Super Group (SGHC) Limited Ordinary Shares pays a 1.8% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Super Group (SGHC) Limited Ordinary Shares for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| SGHC | TNGX | |
|---|---|---|
Market Cap | $5.65B | $3.74B |
Volume | 1,790,497 | 3,438,781 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.59 | $32.90 |
52-Week Low | $8.52 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.19B | $2.76B |
Dividend Yield | 1.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGHC trades at $11.19, down 0.27% with a bearish technical signal despite strong fundamentals. The company shows robust profitability with 53.31% gross margins and 48.9% ROE, while revenue grew to $2.23B in 2025. Recent earnings missed expectations but analyst consensus remains unanimously bullish with 8 buy ratings. Technical indicators show selling pressure with moving averages signaling bearish momentum.
SGHC presents a compelling value opportunity with attractive valuation multiples (P/E 15.55, EV/EBITDA 8.43) and strong cash flow generation. However, recent earnings misses and bearish technical signals create near-term headwinds. The stock's outlook depends on Q3 earnings delivery and sustained sports betting momentum amid competitive pressures.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Super Group (SGHC) Limited Ordinary Shares
Super Group (SGHC) Limited is a holding company for online sports betting and gaming businesses, operating the Betway sports betting brand and the Spin multi-brand online casino portfolio across markets in Europe, the Americas, and Africa.
Read more on SGHC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
